|
Post by robbmo on Sept 8, 2023 13:15:22 GMT -5
This filing is because LQDA filed to have Yutrepia cover PH-ILD as well as PAH. What UTHR is doing is making sure that if UTHR wins the appeal LQDA cannot get Yutrepia approved for PH-ILD. Really this is paperwork though which is why the share price is where it is as nobody expects LQDA to lose that case. If UTHR loses the appeal then the '793 patent is dead and the Hatch-Waxman filing, which this is now part of, is void since you cannot infringe a nonexistent patent. Once again you seemed to ignore that it's not a black & white case... mnkd.proboards.com/post/254256As you and Gregonius (on Stocktwits) speak in definitive terms regarding LQDA 100% winning all the appeals and launching in 2024, I hope people take caution. Not only is it not a certainty that LQDA will prevail, but if they do, it could still take years to go through the appeal process. The other item that I have brought up to Gregonius that he seems to ignore (and you probably will as well) is that the District Courts are not bound by PTAB decisions. The DC ruled that the patent was not invalid. The case is not black & white as you and Gregonius want people to believe, a lot can happen in courts that aren't expected. I've followed other companies that have been in patent disputes where it looked like one side had an iron clad case and end up losing. Again the District Court can supersede the Patent Death Squad aka PTAB and cases can be extended many, many years beyond the averages. Itzafugazi and I have both provided evidence of what I have stated above, so I hope people do their own DD. IMO, UTHR will at the very least do everything they can to drag the cases out to beyond the 2027 patent expiration. What happens when a district court and the PTAB disagree over the validity of a patent?And, if UTHR wins the trade secret theft lawsuit, it won't matter if they lose the PTAB appeals.
|
|
|
Post by agedhippie on Sept 8, 2023 14:37:36 GMT -5
This filing is because LQDA filed to have Yutrepia cover PH-ILD as well as PAH. What UTHR is doing is making sure that if UTHR wins the appeal LQDA cannot get Yutrepia approved for PH-ILD. Really this is paperwork though which is why the share price is where it is as nobody expects LQDA to lose that case. If UTHR loses the appeal then the '793 patent is dead and the Hatch-Waxman filing, which this is now part of, is void since you cannot infringe a nonexistent patent. Once again you seemed to ignore that it's not a black & white case... mnkd.proboards.com/post/254256As you and Gregonius (on Stocktwits) speak in definitive terms regarding LQDA 100% winning all the appeals and launching in 2024, I hope people take caution. Not only is it not a certainty that LQDA will prevail, but if they do, it could still take years to go through the appeal process. The other item that I have brought up to Gregonius that he seems to ignore (and you probably will as well) is that the District Courts are not bound by PTAB decisions. The DC ruled that the patent was not invalid. The case is not black & white as you and Gregonius want people to believe, a lot can happen in courts that aren't expected. I've followed other companies that have been in patent disputes where it looked like one side had an iron clad case and end up losing. Again the District Court can supersede the Patent Death Squad aka PTAB and cases can be extended many, many years beyond the averages. Itzafugazi and I have both provided evidence of what I have stated above, so I hope people do their own DD. IMO, UTHR will at the very least do everything they can to drag the cases out to beyond the 2027 patent expiration. What happens when a district court and the PTAB disagree over the validity of a patent?The District Court can indeed disagree with the PTAB over the validity of the patent, as can the Federal Circuit. There wouldn't be a lot of point in an appeal system where this was otherwise! However, the probabilities are not on UTHR's side based on past records of Federal Circuit appeals. That is what the investors are going on and why the share price isn't about 30% lower than it is. We are past the District Court at this point and at the Federal Circuit from which there is no appeal - this is the end of the road. The courts are always a bit of a lottery but right now LQDA has the edge. If you put a gun to my head I would say there is a 90% chance that LQDA wins this, but absolutely as always there is a chance that they lose. If UTHR loses this appeal then they are done with delaying, the stay is void and the FDA will finalize the approval for Yutrepia for both PAH and PH-ILD ( LQDA cannot sell to the PH-ILD market until April). At that point UTHR is forced to compete by providing better outcomes rather than sheltering behind the courts. Just as I don't want to see Afrezza go away I want to see Yutrepia launched and both for the same reason - people should have choices.
|
|
|
Post by harryx1 on Sept 8, 2023 15:00:41 GMT -5
I think you are missing the point, the '793 was not found invalid by the District Courts therefore there is a potential that even if the PTAB upholds their decision on appeal the DC can still outweigh the PTAB because they us a higher standard to invalidate a patent vs. PTAB. I guess we will see how long UTHR can drag this through the courts (I've seen other companies do similar things approaching 10 years in the courts). When it comes the US courts they are not speedy, maybe the courts in the UK are faster, so in my opinion the timelines you and other LQDA peeps are so adamant on will most likely be a lot longer. I agree people should have choices but when one company potentially steals trade secrets then they shouldn't be allowed to bring their product to market or should be severely sanctioned. We will see how that plays out.
|
|
|
Post by agedhippie on Sept 8, 2023 19:07:30 GMT -5
I think you are missing the point, the '793 was not found invalid by the District Courts therefore there is a potential that even if the PTAB upholds their decision on appeal the DC can still outweigh the PTAB because they us a higher standard to invalidate a patent vs. PTAB. I guess we will see how long UTHR can drag this through the courts (I've seen other companies do similar things approaching 10 years in the courts). When it comes the US courts they are not speedy, maybe the courts in the UK are faster, so in my opinion the timelines you and other LQDA peeps are so adamant on will most likely be a lot longer. I agree people should have choices but when one company potentially steals trade secrets then they shouldn't be allowed to bring their product to market or should be severely sanctioned. We will see how that plays out. I don't think I am missing the point. The Hatch-Waxman District Court ruling didn't find the patent invalid, they found that LQDA was putting the cart in front of the horse. They deferred to the Federal Circuit who have exclusive jurisdiction over patent law and related issue noting in the written decision that they are aware that the PTAB had ruled the patent invalid and that it was under appeal. If the District Court had ruled for LQDA they would have been pre-judging the Federal Circuit appeal and that is not something a District Court ever wants to do. Why do I think UTHR lose the Federal Circuit appeal? Prior art. The inventor published the work at two conferences before the patent was filed creating prior art and getting past that is a heavy lift but not impossible. The court is going to have to decide if the PTAB erred in deciding this is prior art, and as you pointed out courts are nothing if not unpredictable.
|
|
|
Post by agedhippie on Sept 8, 2023 19:31:57 GMT -5
And, if UTHR wins the trade secret theft lawsuit, it won't matter if they lose the PTAB appeals. How long do you think LQDA can drag out that lawsuit, and if LQDA lost what do you think the sanction would be? Bear in mind that the newest of that material is from 2007 so this would relate to the Remodulin generic at best.
|
|
|
Post by wyattdog on Sept 11, 2023 15:22:03 GMT -5
|
|
|
Post by Clement on Oct 2, 2023 15:32:12 GMT -5
Last year, UTHR earnings call was on Nov 2.
|
|
|
Post by wyattdog on Oct 2, 2023 15:48:47 GMT -5
Last year, UTHR earnings call was on Nov 2. found this on Schwab Expected Earnings 3rd Quarter Earnings Announcement Expected: Earnings will tentatively be announced 11/01/2023 before market open. With 11 analysts covering UTHR, the consensus EPS estimate is $5.06, and the high and low estimates are $5.67 and $4.01, respectively.
|
|
|
Post by Clement on Oct 24, 2023 9:11:44 GMT -5
Last year, UTHR earnings call was on Nov 2. So we should see an announcement soon concerning Q3 earnings call.
|
|
|
Post by Clement on Oct 25, 2023 6:59:17 GMT -5
|
|
|
Post by sla55 on Oct 30, 2023 10:08:16 GMT -5
ir.unither.com/news/press-releases/press-release-details/2023/United-Therapeutics-to-Acquire-Miromatrix-Medical/default.aspxUnited Therapeutics to Acquire Miromatrix Medical SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human cells. United Therapeutics is a biotechnology company with six FDA-approved therapies to address rare, life-threatening conditions, and a pipeline that includes four ongoing registration-phase studies. The acquisition of Miromatrix will expand United Therapeutics’ existing complementary platform of organ manufacturing programs, which include ex-vivo lung perfusion, xenotransplantation, 3-D bioprinting, and regenerative medicine approaches with the objective of creating an unlimited supply of tolerable, transplantable organs. “At United Therapeutics, we are determined to rectify the severe shortage of transplantable organs,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “We expect that Miromatrix will help us in this mission, bringing a number of new approaches, highly-skilled personnel, and state of the art facilities as additional shots on goal to complement our existing organ manufacturing programs.” “United Therapeutics’ dedication to solving the chronic shortage of transplantable organs is a vision we share at Miromatrix,” said Jeff Ross, Ph.D., Chief Executive Officer of Miromatrix. “This transaction provides our shareholders with a substantial premium and allows them to participate in the potential upside of our combination, while accelerating the development of our pipeline as we strive to make bioengineered organs a reality for the many patients in need.” Terms of the Agreement United Therapeutics will commence a tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing (an aggregate of approximately $91 million) and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. This transaction is not subject to any financing condition and is expected to close in the fourth quarter of 2023, subject to customary closing conditions, including the tender of a majority of the outstanding shares of Miromatrix’s common stock. Following the successful closing of the tender offer, United Therapeutics will acquire any shares of Miromatrix that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. The purchase price payable at closing represents a premium of approximately 170% to the 30-day volume-weighted average trading price of Miromatrix’s common stock ending on October 27, 2023, the last trading day before the announcement of the transaction. Miromatrix’s Board of Directors unanimously recommends that Miromatrix’s stockholders tender their shares in the tender offer. For United Therapeutics, Gibson, Dunn & Crutcher LLP is acting as legal counsel. For Miromatrix, Piper Sandler is acting as lead financial advisor and Faegre Drinker Biddle & Reath LLP as legal counsel. Craig-Hallum Capital Group LLC also acted as financial advisor to Miromatrix.
|
|
|
Post by wyattdog on Oct 30, 2023 10:31:44 GMT -5
U.S. RESEARCH ROUNDUP- 9:15 AM ET, 10/30/2023 - Reuters United Therapeutics Corp : JP Morgan reinstates with overweight rating, PT $290 *
|
|
|
Post by cretin11 on Oct 30, 2023 10:33:15 GMT -5
170% premium is hefty! Nice day for MIRO shareholders though they've had a tough run to get to this point.
|
|
|
Post by peppy on Oct 30, 2023 13:50:22 GMT -5
UTHR isn't running much today with the over weight reiteration. They did buy Miromatrix for a purchase price of $3.25 per share in cash so an expense. MNKD is running. $4.13 +5.63%. +0.22 UTHR 2nd quarter looked like this, UTHR 2Q 23 Tyvaso revenue was $319.0 million up from $238.4 the previous quarter MNKD 2Q 23 Royalties - $19 million up from $11.678 million the previous quarter Tyvaso revenue was up 33% quarter over quarter Royalties to MNKD were up 62.6% quarter over quarter Wednesday morning will be interesting. "U.S. RESEARCH ROUNDUP- 9:15 AM ET, 10/30/2023 - Reuters United Therapeutics Corp : JP Morgan reinstates with overweight rating, PT $290 *"
|
|
|
Post by castlerockchris on Oct 30, 2023 19:57:20 GMT -5
Gotta say if somebody offered me $11.15 a share for MNKD tomorrow (170% premium), I would be running for the door.
|
|